Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD

PURPOSE: Mucolytics can improve disease outcome in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The objectives of this study were to investigate the effects of erdosteine (ER), a mucolytic agent with antioxidant activity, on systemic inflammation, symptoms, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Moretti, Maurizio, Fagnani, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630194/
https://www.ncbi.nlm.nih.gov/pubmed/26604731
http://dx.doi.org/10.2147/COPD.S87091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630194/
https://www.ncbi.nlm.nih.gov/pubmed/26604731
http://dx.doi.org/10.2147/COPD.S87091

Ejemplares similares